Member Info for RayPointer

Yes, he's a bit of a ****er

Lindy has just passed her GCSE Biology exam :-)

Well I guess not that many folk read the blogs on the Cepi website

hasiba has stopped selling and Cepi have mentioned Scancell in one of their blogs

More like the Cepi surge

Yes but Nottingham is at the centre of the universe. A distinct advantage over the other 299 companies.

https://www.tripadvisor.co.uk/ShowUserReviews-g186356-d11999181-r504092617-The_Mushy_Pea_Stall-Nottingham_Nottinghamshire_England.html

I'm afraid for refreshments only orange juice is served.

I do hope Scancell have a lab. It might be embarrassing for them if Cepi decide to pay them a visit :-)

Yes, Wild it is highly encouraging.
For the people who may have missed it, here it is again

https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/

"For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses.'"

Once again, thanks to Bermuda for finding this.

Could be crumbs. We have to wait and see.
One thing is sure, having a paragraph in a CEPI blog (they have an eye on Scancell) is better than any newspaper publicity.

Thanks for this Bermuda.
This bit is also relevant to Scancell's Immunobody and Avidimab platforms

"Second, we will fund new and innovative platform technologies with the potential to accelerate the development and manufacture of vaccines against previously unknown pathogens (eg: within 16 weeks from identification of antigen to product release for clinical trials)—”just in time”."

I reckon 16 weeks from antigen recognition to clinical trial is possible for Scancell's platforms once the delivery is finalised.
IMO the delivery will be the same for all Immunobody/Avidimab vaccines i.e. attach to soft muscle cells and APCs.

Scancell are in a fascinating situation at present.
With governments obviously worried about new variants and also quick to point out that existing vaccines can be re-engineered to cope with any new variant. It sounds like plan A is possibly to vaccinate the population each year with a revised vaccine. A similar approach to flu vaccination.

I mean we await to see how effective Covidity is against Covid19 and all variants and also how long immunity is likely to last.
Lindy seemed pretty confident on both her conversations with Thomas Moore. I don't think I have seen her so forthright. I think on the first interview she was probably annoyed at not receiving funding at that point.
SCIB1 has already been shown to generate memory T cells. Perhaps these will now be reinforced with the extra help of Avidimab.

Rats
The Aussies really have got the hang of classical music :-)

Here's one of Lindy's team building the cardboard laboratory.
I wouldn't volunteer for a Scancell trial.

https://www.youtube.com/watch?v=jA4CRGJFPE0

Good point krafty.
My inclination would be a less complex deal on Covidity alone with Scancell retaining the IP for Immunobody and Avidimab. Of course, the deal may only be the start for Immunobody/Avidimab for viruses as a whole.
On cancer, with the scib1 combo trial due to restart, I would have thought Scancell would want to get data from this before considering another deal for the cancer side of things. Then there is also the loose end of Scib2 to consider.
It all perhaps points to deals on a product by product basis initially. The added complication is that Avidimab can be applied to Immunobody, but also Lindy has further plans for it in the glycans mabs and indeed any other mab.

No, I am not saying my mates and I have got it right. Only time will answer that question.
Everybody makes their own investment decisions and I genuinely wish you well in yours.

hasiba
On the question of the laboratories I think you need to go to Nottingham to see the building for yourself. I would walk around the building to make sure it is not a cardboard cut-out :-)

Good luck with whatever you decide to do.

Here's confirmation of the location of Scancell's laboratories.

https://www.scancell.co.uk/Data/Sites/1/media/docspres/scancell-interim-results-final-29.01.21.pdf

"Scancell’s laboratories are located at the
Biodiscovery Institute within the University of Nottingham and in line with the University’s policy the laboratory
was closed to most employees in March 2020, except for those working on COVID-19 vaccine development
and maintaining equipment. "

What other questions did you want answers to?

Yes, but if all 11 players surround the referee and complain and gesticulate it can sway the referee's decision.
The Argentinians are good at this.

Much riskier than SCLP I would have thought though, hasiba.
No money and even less clinical data than Scancell.
They also do not appear to have the scientists to improve their products/ invent new products.